AstraZeneca's Calquence Meets Goals in Leukemia Trial
25 Januar 2021 - 8:44AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC said Monday that its Calquence drug showed
greater safety than an existing drug without compromising efficacy
in a phase 3 trial with adults with previously treated, high-risk
chronic lymphocytic leukemia.
The British pharmaceutical giant said Calquence met the primary
goal of demonstrating noninferior progression-free survival in a
head-to-head trial against existing drug ibrutinib.
The drug also met a secondary goal for safety, showing patients
treated with Calquence had statistically significantly lower
incidence of atrial fibrillation compared with patients treated
with ibrutinib, AstraZeneca said.
"The totality of the data confirm our confidence in the
favourable benefit-risk profile of Calquence," AstraZeneca's
Executive Vice President Jose Baselga said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
January 25, 2021 02:29 ET (07:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024